New World Advisors LLC Buys Shares of 1,632 AbbVie Inc. $ABBV

New World Advisors LLC purchased a new position in AbbVie Inc. (NYSE:ABBV) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,632 shares of the company’s stock, valued at approximately $303,000.

A number of other institutional investors have also recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA bought a new position in AbbVie in the 2nd quarter worth about $25,000. TD Capital Management LLC grew its holdings in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the 2nd quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. raised its holdings in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV opened at $236.12 on Friday. The company’s 50 day moving average is $226.81 and its 200 day moving average is $205.22. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company has a market cap of $417.31 billion, a price-to-earnings ratio of 112.44, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 2.9%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Ratings Changes

Several analysts have commented on the company. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Evercore ISI lifted their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. UBS Group upped their target price on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Wells Fargo & Company lifted their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.